Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma

Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) and Neurodegenerative Disorders

(2012) Yu-Chang Chen et al.   MOLECULAR NEUROBIOLOGY

Palmitoylethanolamide Protects Against the Amyloid-β25-35-Induced Learning and Memory Impairment in Mice, an Experimental Model of Alzheimer Disease

(2012) Giuseppe D'Agostino et al.   NEUROPSYCHOPHARMACOLOGY

Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease

(2012) Emanuela Esposito et al.   PLoS One

PPARs at the crossroads of lipid signaling and inflammation

(2012) Walter Wahli et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

New Insights into the Role of Peroxisome Proliferator-Activated Receptors in Regulating the Inflammatory Response after Tissue Injury

(2012) Miriam D. Neher et al.   PPAR Research

The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications

(2012) Elisa Benetti et al.   Endocrine Metabolic & Immune Disorders-Drug Targets

Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury

(2011) Emanuela Esposito et al.   BRAIN BEHAVIOR AND IMMUNITY

Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain

(2010) Harald S. Hansen   EXPERIMENTAL NEUROLOGY

Evidence for the Role of Peroxisome Proliferator-Activated Receptor- /  in the Development of Spinal Cord Injury

(2010) I. Paterniti et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome

(2010) Teresa Coll et al.   Current Molecular Pharmacology

Behavioral Effects of CB2 Cannabinoid Receptor Activation and Its Influence on Food and Alcohol Consumption

(2009) E. S. Onaivi et al.   Annals of the New York Academy of Sciences

Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia

(2009) Giuseppe D'Agostino et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice

(2009) Oscar Sasso et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease

(2009) S.E. O'Sullivan et al.   IMMUNOBIOLOGY

Peroxisome Proliferator-activated Receptor γ Down-regulates Follistatin in Intestinal Epithelial Cells through SP1

(2008) Brian M. Necela et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of Palmitoylethanolamide on Signaling Pathways Implicated in the Development of Spinal Cord Injury

(2008) T. Genovese et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Integration of metabolism and inflammation by lipid-activated nuclear receptors

(2008) Steven J. Bensinger et al.   NATURE

The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors

(2008) Barbara Costa et al.   PAIN